Differential regulation of the mouse and human wnt5a alternative promoters A and B

DNA and Cell Biology

Volumn 31, Issue 11, 2012, Pages 1585-1597

  Katula, Karen S ^a   Joyner Powell, Nicole B ^b   Hsu, Chia Chi ^c   Kuk, Amber ^d  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^b OHIO UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; WNT5A PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TYPE; CONTROLLED STUDY; EXON; FIBROBLAST; INTRON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANIMALS; BASE SEQUENCE; BUTADIENES; CACO-2 CELLS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; LUCIFERASES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NF-KAPPA B; NIH 3T3 CELLS; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENYLENEDIAMINES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; WNT PROTEINS;

EID: 84868032777     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2012.1698     Document Type: Article

References (50)

1. Applied Biosystems. (2006). Application Note: TaqMan Gene Expression Assay. Publication 127APO5-03 (Foster City, CA).
2. Baek, D., Davis, C., Ewing, B., Gordon, D., and Green, P. (2007). Characterization and predictive discovery of evolutionarily conserved mammalian alternative promoters. Genome Res 17, 125-155.
3. Banday, A.R., Azim, S., and Tabish, M. (2011). Alternative promoter usage and differential expression of multiple transcripts of mouse Prkar1a gene. Mol Cell Biochem 357, 263-274.
4. Basseres, D.S., and Baldwin, A.S. (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817-6830.
5. Bee, T., Swiers, G., Muroi, S., Nottingham, W., Santos, A.C., Li, P.S., et al. (2010). Nonredundant roles for Runx1 alternative promoters reflect their activity at discrete stages of developmental hematopoiesis. Blood 115, 3042-3050.
6. Bilkovski, R., Schulte, D.M., Oberhauser, F., Gomolka, M., Udelhoven, M., Hettich, M.M., et al. (2010). Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J Biol Chem 285, 6170-6178.
7. Blakely, B.D., Bye, C.R., Fernando, C.V., Horne, M.K., Macheda, M.L., Stacker, S.A., et al. (2011). Wnt5a regulates midbrain dopaminergic axon growth and guidance. PLoS One 6, e18373.
8. Demura, M., Demura, Y., Ameshima, S., Ishizaki, T., Sasaki, M., Miyamori, I., et al. (2011). Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer. Lung Cancer 73, 289-293.
9. Deng, G., Li, Z.Q., Zhao, C., Yuan, Y., Niu, C.C., Pan, J., et al. (2011). WNT5A expression is regulated by the status of its promoter methylation in leukaemia and can inhibit leukemic cell malignant proliferation. Oncol Rep 25, 367-376.
10. Dissanayake, S.K., Wade, M., Johnson, C.E., O'Connell, M.P., Leotlela, P.D., French, A.D., et al. (2007). The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 282, 17259- 17271.
11. Enomoto, M., Hayakawa, S., Itsukushima, S., Ren, D.Y., Matsuo, M., Tamada, K., et al. (2009). Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 28, 3197-3208.
12. Flicek, P., Amode, M.R., Barrell, D., Beal, K., Brent, S., Carvalho- Silva, D., et al. (2012). Ensembl 2012. Nucleic Acids Res 40, D84-D90.
13. Ge, X.P., Gan, Y.H., Zhang, C.G., Zhou, C.Y., Ma, K.T., Meng, J.H., et al. (2011). Requirement of the NF-kappaB pathway for induction of Wnt-5A by interleukin-1beta in condylar chondrocytes of the temporomandibular joint: functional crosstalk between the Wnt-5A and NF-kappaB signaling pathways. Osteoarthritis Cartilage 19, 111-117.
14. Hardy, K.M., Garriock, R.J., Yatskievych, T.A., D'Agostino, S.L., Antin, P.B., and Krieg, P.A. (2008). Non-canonical Wnt signaling through Wnt5a/b and a novel Wnt11 gene, Wnt11b, regulates cell migration during avian gastrulation. Dev Biol 320, 391-401.
15. Hibi, K., Mizukami, H., Goto, T., Kitamura, Y., Sakata, M., Saito, M., et al. (2009). WNT5A gene is aberrantly methylated from the early stages of colorectal cancers. Hepatogastroenterology 56, 1007-1009.
16. Huang, C.L., Liu, D., Nakano, J., Ishikawa, S., Kontani, K., Yokomise, H., et al. (2005). Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor - an expression in non-small-cell lung cancer. J Clin Oncol 23, 8765-8773.
17. Iozzo, R.V., Eichstetter, I., and Danielson, K.G. (1995). Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55, 3495-3499.
18. Katoh, M., and Katoh, M. (2007). STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer. Int J Mol Med 19, 273-278.
19. Katoh, M., and Katoh, M. (2009). Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 23, 763-769.
20. Kikuchi, A., Yamamoto, H., Sato, A., and Matsumoto, S. (2011). Wnt5a: its signaling, functions and implication in diseases. Acta Physiol (Oxf) 204, 17-33.
21. Kimura, K., Wakamatsu, A., Suzuki, Y., Ota, T., Nishikawa, T., et al. (2006). Diversification of transcriptional modulation: Large-scale identification and characterization of putative alternative promoters of human genes. Genome Res 16, 55-65.
22. Kurayoshi, M., Oue, N., Yamamoto, H., Kishida, M., Inoue, A., Asahara, T., et al. (2006). Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66, 10439-10448.
23. Li, J., Ying, J., Fan, Y., Wu, L., Ying, Y., Chan, A.T., et al. (2010). WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther 10, 617-624.
24. Liang, H., Chen, Q., Coles, A.H., Anderson, S.J., Pihan, G., Bradley, A., et al. (2003). Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4, 349-360.
25. Liang, S.H., Hassett, C., and Omiecinski, C.J. (2005). Alternative promoters determine tissue-specific expression profiles of the human microsomal epoxide hydrolase gene (EPHX1). Mol Pharm 67, 220-230.
26. Liu, S. (2010). Increasing alternative promoter repertories is positively associated with differential expression and disease susceptibility. PLoS One 5, e9482.
27. Ma, L., and Wang, H.Y. (2007). Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2 + non-canonical pathway. J Biol Chem 282, 28980-28990.
28. Martin, V., Valencia, A., Agirre, X., Cervera, J., San Jose-Eneriz, E., Vilas-Zornoza, A., et al. (2009). Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. Cancer Sci 101, 425-432.
29. McCall, K.D., Harii, N., Lewis, C.J., Malgor, R., Kim, W.B., Saji, M., et al. (2007). High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 148, 4226-4237.
30. McDonald, S.L., and Silver, A. (2009). The opposing roles of Wnt-5a in cancer. Br J Cancer 101, 209-214.
31. Michl, P., Ramjaun, A., Pardo,O., Warne, P.,Wagner, M., Poulsom, R., D'Arrigo, C., Ryder, K.,Menke, A., Gress, T., and Downward, J. (2005). CUTL1 is a Target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521-532.
32. Mikels, A.J., and Nusse, R. (2006). Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4, e115.
33. Nakano, T., Tani, M., Ishibashi, Y., Kimura, K., Park, Y.B., Imaizumi, N., et al. (2003). Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis 20, 665-674.
34. Oh, S.Y., Lee, M.Y., Kim, J.M., Yoon, S., Shin, S., Park, Y.N., et al. (2005). Alternative usages of multiple promoters of the acetyl- CoA carboxylase b gene are related to differential transcriptional regulation in human and rodent tissues. J Biol Chem 280, 5909-5916.
35. Pukrop, T., Klemm, F., Hagemann, T., Gradl, D., Schulz, M., Siemes, S., et al. (2006). Wnt 5a signaling is critical for macrophage- induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A 103, 5454-5459.
36. Rauner, M., Stein, N., Winzer, M., Goettsch, C., Zwerina, J., Schett, G., et al. (2012). WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 27, 575-585.
37. Ripka, S., Konig, A., Buchholz, M., Wagner, M., Sipos, B., Kloppel, G., et al. (2007). WNT5A - target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28, 1178-1187.
38. Roman-Gomez, J., Jimenez-Velasco, A., Cordeu, L., Vilas-Zornoza, A., San Jose-Eneriz, E., Garate, L., et al. (2007). WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. Eur J Cancer 43, 2736-2746.
39. Saitoh, T., and Katoh, M. (2002). Expression and regulation of WNT5A and WNT5B in human cancer: up-regulation of WNT5A by TNFalpha in MKN45 cells and up-regulation of WNT5B by beta-estradiol in MCF-7 cells. Int J Mol Med 10, 345-349.
40. Saitoh, T., Mine, T., and Katoh, M. (2002). Frequent up-regulation of WNT5A mRNA in primary gastric cancer. Int J Mol Med 9, 515-519.
41. Schwartz, A.L., Malgor, R., Dickerson, E., Weeraratna, A.T., Slominski, A., Wortsman, J., et al. (2009). Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res 15, 4114-4122.
42. Taki, M., Kamata, N., Yokoyama, K., Fujimoto, R., Tsutsumi, S., and Nagayama, M. (2003). Down-regulation of Wnt-4 and upregulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci 94, 593-597.
43. Tamimi, Y., Ekuere, U., Laughton, N., and Grundy, P. (2008). WNT5A is regulated by PAX2 and may be involved in blastemal predominant Wilms tumorigenesis. Neoplasia 10, 1470-1480.
44. Wang, Q., Williamson, M., Bott, S., Brookman-Amissah, N., Freeman, A., Nariculam, J., et al. (2007). Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 26, 6560-6565.
45. Wang, Z., and Chen, H. (2009). Amino acid limitation induces down-regulation of WNT5a at transcriptional level. Biochem Biophys Res Commun 378, 789-794.
46. Weeraratna, A.T., Houben, R., O'Connell, M.P., and Becker, J.C. (2010). Lack of Wnt5A expression in Merkel cell carcinoma. Arch Dermatol 146, 88-89.
47. Weeraratna, A.T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., et al. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
48. Yamaguchi, T.P., Bradley, A., McMahon, A.P., and Jones, S. (1999). A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126, 1211-1223.
49. Yang, Y., Topol, L., Lee, H., and Wu, J. (2003). Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 130, 1003-1015.
50. Ying, J., Li, H., Yu, J., Ng, K.M., Poon, F.F., Wong, S.C., et al. (2008). WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 14, 55-61.